October 1 - 4, 2017
Boston Marriott Copley Hotel
Abstract submission deadline: Friday, July 14
Advance registration deadline: Friday, September 8
Accreditation StatementThe American Association for Cancer Research (AACR) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education activities for physicians.
Credit Designation StatementThe AACR has designated this live activity for a maximum of 18.75 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Credit certification for individual sessions may vary, dependent upon compliance with the ACCME Accreditation Criteria. The final number of credits may vary from the maximum number indicated above.
Claiming (CME) CreditPhysicians and other health care professionals seeking AMA PRA Category 1 Credit(s)TM for this live continuing medical education activity must complete the CME Request for Credit Survey by Wednesday, November 15, 2017. Certificates will only be issued to those who complete the survey. Your CME certificate will be sent to you via email after the completion of the activity.REQUEST FOR CREDIT SURVEY
Statement of Educational Need, Target Audience, and Learning ObjectivesIn 2017, there will be
an estimated 1,688,780 new cancer cases diagnosed and 600,920 cancer deaths in
the US. Almost 40% of men and women will be diagnosed with cancer during their
lifetimes. While surgery, chemotherapy and radiotherapy have been the mainstay
of cancer treatments, these have significant side effects and are often
ineffective. Novel, safe and tolerable therapeutic approaches are greatly
Utilizing the body’s
immune system to fight cancer is often safer and better tolerated than
traditional cancer treatments such as chemotherapy and radiation. Study and
understanding of the immune system’s response to cancer has increased
exponentially over the past several years, and this has given rise to many
breakthrough cancer treatments. Types of immunotherapies include monoclonal
antibodies (including checkpoint inhibitors), adoptive cell transfer (including
CAR T cell therapy), therapeutic vaccines, cytokines, and oncolytic viruses.
treatments include monoclonal antibodies; radio- or chemolabeled monoclonal
antibodies; bispecific monoclonal antibodies; checkpoint inhibitors such as
PD-1, PD-L1, and CTLA-4 inhibitors, which have been approved for treatment of
many cancers; cancer vaccines for treatment and prevention, cytokines such as interleukins
and interferons; and immunomodulatory drugs that boost immune system function.
This conference will
feature some of the world’s premier oncologists who will present their latest
research on current immunotherapies. It will also help bridge the gap between
the advances that are underway in the lab and their application to clinical
practice. Particularly, this conference will feature talks from scientists
working in cutting edge fields such as neoantigens and synthetic biology, as
well as different perspectives of metabolism, the microbiome, and whole systems
biology, which will lead to a deeper understanding of the immune response to
Physicians require a
solid and current understanding of immunology to stratify patients according to
tumor type and the characteristics of their tumor microenvironments, predict
responses and determine the best personalized treatment plan. In addition, it
has recently become apparent that conventional therapies (surgery,
chemotherapy, and radiotherapy), as well as targeted agents, affect the
patient’s immune system. An improved understanding of these effects will enable
physicians to treat patients more effectively.
After participating in this CME activity, physicians should be able to:
1. Identify and integrate novel strategies for visualizing tumors.2. Evaluate novel biomarkers or neoantigens, and genomics to assess patients’ individual cancer, potential responses to treatment3. Explain the role of the gut and metabolism in tumor progression.4. Explain the role of immunomodulatory cells in inflammation and in the tumor microenvironment5. Integrate novel combination therapies and engineered immune cells for personalizing cancer immune responses.
1. Identify and integrate novel strategies for visualizing tumors.
2. Evaluate novel biomarkers or neoantigens, and genomics to assess patients’ individual cancer, potential responses to treatment
3. Explain the role of the gut and metabolism in tumor progression.
4. Explain the role of immunomodulatory cells in inflammation and in the tumor microenvironment
5. Integrate novel combination therapies and engineered immune cells for personalizing cancer immune responses.
Disclosure StatementIt is the policy of the AACR that the information presented at AACR CME activities will be unbiased and based on scientific evidence. To help participants make judgments about the presence of bias, the AACR will provide information that Program Committee members and speakers have disclosed about financial relationships they have with commercial entities that produce or market products or services related to the content of this CME activity. This disclosure information will be made available in the Program/Proceedings of this conference.
Acknowledgement of Financial or Other SupportThis activity is supported by grants and will be disclosed at the activity.
Questions about CME?Please contact the Office of CME at 215-440-9300 or firstname.lastname@example.org.